Add-On Clarithromycin Pans Out in Community-Acquired Pneumonia Trial
(MedPage Today) -- In a phase III trial, the addition of oral clarithromycin to beta-lactam antibiotic treatment improved the clinical response of people with community-acquired pneumonia who had systemic inflammatory response syndrome, findings... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - January 11, 2024 Category: American Health Source Type: news

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for Voquezna Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquezna Dual Pak (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
FLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced that the U.S.... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 31, 2023 Category: Drugs & Pharmacology Source Type: news

Antibiotic shortages reported as prescribing increases over strep A concerns
Pharmacists are reporting shortages of some antibiotics, including amoxicillin and clarithromycin oral suspensions, as GPs are being urged to have a ' low threshold ' for prescribing in children presenting with symptoms of Group A streptococcal infection. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 7, 2022 Category: Consumer Health News Source Type: news

Time to Ditch Clarithromycin for H pylori? Time to Ditch Clarithromycin for H pylori?
High clarithromycin resistance rates among H pylori isolates in the United States and Europe are grounds for arguing against its use in PPI-based triple therapy, researchers say.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 21, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial
Conclusions: Clarithromycin did not reduce mortality among patients with sepsis with respiratory and multiple organ dysfunction. Clarithromycin was associated with lower sepsis recurrence, possibly through a mechanism of immune restoration (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 30, 2022 Category: Consumer Health News Source Type: news

Catalent Supports U.S. Launch of Phathom Pharmaceuticals ’ New Products...
Catalent today welcomed the recent announcement by Phathom Pharmaceuticals that the U.S. FDA has approved both VOQUEZNA™ TRIPLE PAK™ (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets)...(PRWeb June 09, 2022)Read the full story at https://www.prweb.com/releases/catalent_supports_u_s_launch_of_phathom_pharmaceuticals_new_products_following_regulatory_approval/prweb18728261.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 9, 2022 Category: Pharmaceuticals Source Type: news

Two New Regimens Win FDA Approval for H. Pylori Infection
(MedPage Today) -- The FDA approved two vonoprazan-based regimens, one with amoxicillin and clarithromycin (Voquezna Triple Pak), and one with amoxicillin (Voquezna Dual Pak), to treat Helicobacter pylori (H. pylori) infection in adults, drugmaker... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 4, 2022 Category: American Health Source Type: news

FDA Approves Voquezna Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquezna Dual Pak (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
Voquezna Triple and Dual Paks each contain vonoprazan, a novel, first-in-class potassium-competitive acid blocker (PCAB), and have demonstrated superior eradication rates vs. lansoprazole-based triple therapy in the overall... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 4, 2022 Category: Drugs & Pharmacology Source Type: news

Alembic gets USFDA approval to market Clarithromycin tablets in America
Alembic's product is therapeutically equivalent to AbbVie Inc's Biaxin Filmtab Tablets, which is antimicrobial indicated to treat mild to moderate infections caused by designated, susceptible bacteria. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 1, 2022 Category: Pharmaceuticals Source Type: news

Vonoprazan Beats PPIs in H pylori Eradication Vonoprazan Beats PPIs in H pylori Eradication
The oral potassium-competitive acid blocker was especially better against clarithromycin-resistant strains.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 3, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Clinicians May Overprescribe Clarithromycin for H pylori Clinicians May Overprescribe Clarithromycin for H pylori
Most physicians start patients with H pylori infection on clarithromycin, despite high rates of resistance.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 30, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Cholestenone shows antibiotic properties against H. pylori
(Shinshu University) Helicobacter pylori, a gram-negative pathogen that has infected half of the world's population is a Group I carcinogen according to the WHO. H. pylori resides in the gastric mucosa causing gastritis, ulcers, gastric cancers and gastric malignant lymphoma. It can be eradicated in most infected people using a combination of three drugs including antibiotics clarithromycin. However drug-resistant H. Pylori is a growing problem and it is expected to develop drugs that exhibit anti-H. pylori activity. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 27, 2021 Category: International Medicine & Public Health Source Type: news

What are Potential Problems Associated with Helicobacter pylori?
Discussion Helicobacter pylori (H. pylori) is a microaerophilis, spiral bacterium that is a prevalent human pathogen. How this infection affects individuals is different in adults and children. Overall seroprevalence rate in children world-wide was estimated to be ~33%, but this seroprevalence rate is decreasing in the developed world for both adults and children. It is acquired in childhood and can persist through colonization throughout life if untreated. Fortunately, it often is asymptomatic and generally does not cause serious disease in children. Some serotyping data shows that within families children acquire it more...
Source: PediatricEducation.org - November 23, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

More about chloroquine and hydroxychloroquine, CEBM (updated 30th August 2020)
VERDICT The hypothesis that the 4-aminoquinolines chloroquine and hydroxychloroquine may be beneficial in the treatment of COVID-19 is a weak one, based on poor mechanistic reasoning and inconsistent results of studies in vitro, in laboratory animals, and in humans. It is likely that even if chloroquine and hydroxychloroquine are effective in COVID-19, the beneficial effects will be small. The risks of adverse reactions to these drugs may be increased in patients who are acutely ill with severe COVID-19, in many of whom high doses are being used. Macrolide antibacterial drugs, such as azithromycin, clarithromycin, ery...
Source: Current Awareness Service for Health (CASH) - September 2, 2020 Category: Consumer Health News Source Type: news

More about chloroquine and hydroxychloroquine, CEBM
VERDICT: The hypothesis that the 4-aminoquinolines chloroquine and hydroxychloroquine may be beneficial in the treatment of COVID-19 is a weak one, based on poor mechanistic reasoning and inconsistent results of studies in vitro, in laboratory animals, and in humans. It is likely that even if chloroquine and hydroxychloroquine are effective in COVID-19, the beneficial effects will be small. The risks of adverse reactions to these drugs may be increased in patients who are acutely ill with severe COVID-19, in many of whom high doses are being used. Macrolide antibacterial drugs, such as azithromycin, clarithromycin, ery...
Source: Current Awareness Service for Health (CASH) - June 1, 2020 Category: Consumer Health News Source Type: news